Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-15a641fc1891be6ddabc72928a523139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-15a641fc1891be6ddabc72928a523139",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-15a641fc1891be6ddabc72928a523139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-15a641fc1891be6ddabc72928a523139\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-15a641fc1891be6ddabc72928a523139</b></p><a name=\"composition-en-15a641fc1891be6ddabc72928a523139\"> </a><a name=\"hccomposition-en-15a641fc1891be6ddabc72928a523139\"> </a><a name=\"composition-en-15a641fc1891be6ddabc72928a523139-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1778/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - naveruclif</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1778/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp15a641fc1891be6ddabc72928a523139"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - naveruclif",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Naveruclif is and what it is used for</li><li>What you need to know before you are given Naveruclif</li><li>How to use Naveruclif</li><li>Possible side effects</li><li>How to store Naveruclif</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What naveruclif is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What naveruclif is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Naveruclif contains, as its active substance, paclitaxel attached to the human protein albumin, in the form of tiny particles known as nanoparticles. Paclitaxel belongs to a group of medicines called taxanes used in cancer.</p><p>Paclitaxel is the part of the medicine that affects the cancer, it works by stopping cancer cells from dividing this means that they die.</p><p>Albumin is the part of the medicine that helps paclitaxel dissolve in the blood and get across the walls of the blood vessels into the tumour. This means that other chemicals that can cause side effects that can be life threatening are not needed. Such side effects occur far less with Naveruclif.</p><p>What Naveruclif is used for Naveruclif is used to treat the following types of cancer:</p><p>Breast Cancer</p><p>Breast cancer which has spread to other parts of the body (this is called metastatic breast cancer).</p><p>Naveruclif is used in metastatic breast cancer when at least one other therapy has been tried but has not worked and you are unsuitable for treatments containing a group of medicines called anthracyclines .</p><p>People with metastatic breast cancer who received Naveruclif where another therapy had failed, were more likely to experience a reduction in tumour size, and lived longer than people who took an alternative therapy.</p><p>Pancreatic Cancer</p><p>Naveruclif is used together with a medicine called gemcitabine if you have metastatic cancer of the pancreas. People with metastatic pancreatic cancer (pancreatic cancer that has spread to other parts of the body) who received Naveruclif with gemcitabine in a clinical trial lived longer than people who had only received gemcitabine.</p><p>Lung Cancer</p><p>Naveruclif is also used together with a medicine called carboplatin if you have the most common type of lung cancer, called non-small cell lung cancer .</p><p>Naveruclif is used in non-small cell lung cancer where surgery or radiotherapy would not be suitable to treat the disease.</p></div>"
}
},
{
"title" : "2. What you need to know before you take naveruclif",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take naveruclif"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use Naveruclif</p><p>if you are allergic to Paclitaxel or any of the other ingredients of this medicine (listed in section 6).</p><p>if you are breast-feeding</p><p>if you have a low white blood cell count (baseline neutrophil counts <1500 cells/mm3 - your doctor will advise you on this).</p><p>Warnings and precautions<br/>Talk to your doctor or nurse before using Naveruclif</p><p>if you have poor kidney function;</p><p>if you have severe liver problems;</p><p>if you have heart problems.</p><p>Talk to your doctor or nurse if you experience any of these conditions whilst being treated with Naveruclif, your doctor may wish to stop treatment or reduce the dose:</p><p>if you experience any abnormal bruising, bleeding, or signs of infections such as a sore throat or a fever;</p><p>if you experience numbness, tingling, pricking sensations, sensitivity to touch, or muscle weakness;</p><p>if you experience breathing problems, like shortness of breath or dry cough.</p><p>Children and adolescents Naveruclif is only for adults and should not be taken by children and adolescents aged below 18 years.</p><p>Other medicines and Naveruclif Tell your doctor if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Naveruclif can affect the way some other medicines work. Also, some other medicines can affect the way Naveruclif works.</p><p>Take care and speak to your doctor when taking Naveruclif at the same time as any of the following:</p><p>medicines for treating infections (i.e. antibiotics such erythromycin, rifampicin, etc.; ask your doctor, nurse or pharmacist if you are unsure whether the medicine you are taking is an antibiotic), and including medicines for treating fungal infections (e.g. ketoconazole)</p><p>medicines used to help you stabilize your mood also sometimes referred to as anti-depressants (e.g. fluoxetine)</p><p>medicines used to treat seizures (epilepsy) (e.g. carbamazepine, phenytoin)</p><p>medicines used to help you lower blood lipid levels (e.g. gemfibrozil)</p><p>medicine used for heartburn or stomach ulcers (e.g. cimetidine)</p><p>medicines used to treat HIV and AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, nevirapine)</p><p>a medicine called clopidogrel used to prevent blood clots.</p><p>Pregnancy, breast-feeding and fertility Paclitaxel may cause serious birth defects and should therefore not be used if you are pregnant. Your doctor will arrange a pregnancy test before starting treatment with Naveruclif.</p><p>Women of childbearing age should use effective contraception during and up to 1 month after receiving treatment with Naveruclif.</p><p>Do not breast feed when taking Naveruclif as it is not known if the active ingredient paclitaxel passes into the mother s milk.</p><p>Male patients are advised to use effective contraception and to avoid fathering a child during and up to six months after treatment and should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Naveruclif.</p><p>Ask your doctor for advice before taking this medicine.</p><p>Driving and using machines Some people may feel tired or dizzy after being given Naveruclif. If this happens to you, do not drive or use any tools or machines.</p><p>If you are given other medicines as part of your treatment, you should ask your doctor for advice on driving and using machines.</p><p>Naveruclif contains sodium This medicine contains less than 1 mmol sodium (23 mg) per 100 mg, that is to say essentially sodium free .</p></div>"
}
},
{
"title" : "3. How to take naveruclif",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take naveruclif"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Naveruclif will be given to you by a doctor or nurse into a vein from an intravenous drip. The dose you receive is based on your body surface area and blood test results. The usual dose is for breast cancer is 260 mg/m2 of body surface area given over a 30 minute period. The usual dose for advanced pancreatic cancer is 125 mg/m2 of body surface area given over a 30 minute period. The usual dose for non-small cell lung cancer is 100 mg/m2 of body surface area given over a 30 minute period.</p><p>How often will you receive Naveruclif? For treatment of metastatic breast cancer, Naveruclif is usually given once every three weeks (on day 1 of a 21-day cycle).</p><p>For treatment of advanced pancreatic cancer, Naveruclif is given on days 1, 8 and 15 of each 28-day treatment cycle with gemcitabine being given immediately after the Naveruclif.</p><p>For treatment of non-small cell lung cancer Naveruclif is given once every week (i.e. on days 1, 8 and 15 of a 21-day cycle), with carboplatin being given once every three weeks (i.e. only on day 1 of each 21-day cycle), immediately after the Naveruclif dose has been given.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The very common side effects may affect more than 1 in 10 people:</p><p>Loss of hair (the majority of cases of hair loss happened less than one month after starting Naveruclif. When it happens, hair loss is pronounced (over 50%) in the majority of patients)</p><p>Rash</p><p>Abnormal decrease in the number of types of white blood cells (neutrophils, lymphocytes or leukocytes) in the blood</p><p>Deficiency of red blood cells</p><p>Reduction in the number of platelets in the blood</p><p>Effect on peripheral nerves (pain, numbness, tingling or loss of feeling)</p><p>Pain in a joint or joints</p><p>Pain in the muscles</p><p>Nausea, diarrhoea, constipation, sore mouth, loss of appetite</p><p>Vomiting</p><p>Weakness and tiredness, fever</p><p>Dehydration, taste disturbance, weight loss</p><p>Low levels of potassium in the blood</p><p>Depression, sleep problems</p><p>Headache</p><p>Chills</p><p>Difficulty in breathing</p><p>Dizziness</p><p>Swelling of mucosal and soft tissues</p><p>Increased liver function tests</p><p>Pain in extremities</p><p>Cough</p><p>Abdominal pain</p><p>Nose bleeds</p><p>The common side effects may affect up to 1 in 10 people:</p><p>Itching, dry skin, nail disorder</p><p>Infection, fever with decrease in the number of a type of white blood cell (neutrophils) in the blood, flushing, thrush, severe infection in your blood which may be caused by reduced white blood cells</p><p>Reduction in all blood cell counts</p><p>Chest or throat pain</p><p>Indigestion, abdominal discomfort</p><p>Stuffy nose</p><p>Pain in back, bone pain</p><p>Diminished muscular coordination or difficulty in reading, increased or decreased tears, loss of eyelashes</p><p>Changes in heart rate or rhythm, heart failure</p><p>Decreased or increased blood pressure</p><p>Redness or swelling at the site where the needle entered the body</p><p>Anxiety</p><p>Infection in the lungs</p><p>Infection in the urinary tract</p><p>Obstruction in the gut, inflammation of the large bowel, inflammation of the bile duct</p><p>Acute kidney failure</p><p>Increased bilirubin in the blood</p><p>Coughing up blood</p><p>Dry mouth, difficulty in swallowing</p><p>Muscle weakness</p><p>Blurred vision</p><p>The uncommon side effects may affect up to 1 in 100 people:</p><p>Increased weight, increased lactate dehydrogenase in the blood, decreased kidney function, increased blood sugar, increased phosphorus in the blood</p><p>Decreased or lack of reflexes, involuntary movements, pain along a nerve, fainting, dizziness when standing up, shaking, facial nerve paralysis</p><p>Irritated eyes, painful eyes, red eyes, itchy eyes, double vision, reduced vision, or seeing flashing lights, blurred vision due to swelling of the retina (cystoid macular oedema)</p><p>Ear pain, ringing in your ears</p><p>Coughing with phlegm, shortness of breath when walking or climbing stairs, runny nose, or dry nose, decreased breath sounds, water on the lung, loss of voice, blood clot in the lung, dry throat</p><p>Gas, stomach cramps, painful or sore gums, rectal bleeding</p><p>Painful urination, frequent urination, blood in the urine, inability to hold your urine</p><p>Fingernail pain, fingernail discomfort, loss of fingernails, hives, skin pain, red skin from sunlight, skin discolouration, increased sweating, night sweats, white areas on the skin, sores, swollen face</p><p>Decreased phosphorus in the blood, fluid retention, low albumin in the blood, increased thirst, decreased calcium in the blood, decreased sugar in the blood, decreased sodium in the blood</p><p>Pain and swelling in the nose, skin infections, infection due to catheter line</p><p>Bruising</p><p>Pain at site of tumour, death of the tumour</p><p>Decreased blood pressure when standing up, coldness in your hands and feet</p><p>Difficulty walking, swelling</p><p>Allergic reaction</p><p>Decreased liver function, increased size of liver</p><p>Pain in the breast</p><p>Restlessness</p><p>Small bleedings in your skin due to blood clots</p><p>A condition involving destruction of red blood cells and acute kidney failure</p><p>The rare side effects may affect up to 1 in 1,000 people:</p><p>Skin reaction to another agent or lung inflammation following radiation</p><p>Blood clot</p><p>Very slow pulse, heart attack</p><p>Leaking of drug outside the vein</p><p>A disorder of the electrical conduction system of the heart (atrioventricular block)</p><p>The very rare side effects may affect up to 1 in 10,000 people:</p><p>Severe inflammation/eruption of the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis)</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>Hardening/thickening of the skin (scleroderma)</p><p>Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store naveruclif",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store naveruclif"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p>Unopened vials: Keep the vial in the outer carton in order to protect from light.</p><p>After first reconstitution the dispersion should be used immediately. If not used immediately, the dispersion may be stored in a refrigerator (2 C-8 C) for up to 24 hours in the vial when kept in the outer carton in order to protect it from light.</p><p>The reconstituted dispersion in the intravenous drip may be stored in a refrigerator (2 C-8 C) for up to 24 hours protected from light.</p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at 2 C-8 C when protected from light followed by 4 hours at 25 C when not protected from light.</p><p>Your doctor or pharmacist is responsible for disposing of any unused Naveruclif correctly.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Naveruclif contains</p><p>The active substance(s) is paclitaxel. Each vial contains 100 mg of paclitaxel formulated as albumin bound nanoparticles. After reconstitution, each ml of dispersion contains 5 mg of paclitaxel formulated as albumin bound nanoparticles.</p><p>The other ingredient is albumin (human) (containing sodium caprylate and N-acetyl-L- tryptophan), see section 2 Naveruclif contains sodium .</p><p>What Naveruclif looks like and contents of the pack</p><p>Naveruclif is a white to yellow powder or lyophilized cake for dispersion for infusion. Naveruclif is available in glass vials containing 100 mg of paclitaxel formulated as albumin bound nanoparticles.</p><p>Each pack contains 1 vial.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorization Holder Accord Healthcare S.L.U. World Trade Center, Moll De Barcelona s/n,<br/>Edifici Est, 6a Planta,<br/>Barcelona, 08039,<br/>Spain</p><p>Manufacturer<br/>Accord Healthcare Polska Sp.z o.o. ul. Lutomierska 50, 95-200 Pabianice, Poland</p><p>Or Laboratori Fundaci Dau C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona, 08040, Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>AT / BE / BG / CY / CZ / DE / DK / EE / ES / FI / FR / HR / HU / IE / IS / IT / LT / LV / LX / MT / NL / NO / PL / PT / RO / SE / SI / SK / UK (NI)</p><p>Accord Healthcare S.L.U.<br/>Tel: +34 93 301 00 EL<br/>Win Medica . . : +30 210 74 88 This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp15a641fc1891be6ddabc72928a523139",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp15a641fc1891be6ddabc72928a523139",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp15a641fc1891be6ddabc72928a523139\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp15a641fc1891be6ddabc72928a523139</b></p><a name=\"mp15a641fc1891be6ddabc72928a523139\"> </a><a name=\"hcmp15a641fc1891be6ddabc72928a523139\"> </a><a name=\"mp15a641fc1891be6ddabc72928a523139-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1778/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Naveruclif 5 mg/ml powder for dispersion for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1778/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Naveruclif 5 mg/ml powder for dispersion for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
